Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,079 total articles
Toast is a mission-critical point-of-sale and restaurant management platform trading near its 52-week low. With $608M in free cash flow, $1.4B in cash, healthy liquidity ratios, and high customer integration, Toast looks better insulated from the latest 'SaaSpocalypse' headlines. The trade: initiate a long at $25.00, stop at $22.50, target $40.00 o…
Cullinan Therapeutics (CGEM) looks like a tactical long: clinical momentum around its CD19 T-cell engager CLN-978, positive data flow from zipalertinib, and a multi-hundred-million dollar cash position reduce near-term financing risk. We outline an actionable trade with entry at $14.00, stop at $11.00 and a $22.00 target over a 180 trading-day hori…
Newmont has turned rock into cash: $7.3B of free cash flow, a sub-0.2 debt/equity ratio and double-digit returns on capital give the company both optionality and room to return capital. With gold still above pre-surge levels and miners trading on reasonable multiples (P/E ~19, EV/EBITDA ~9.9), we like a tactical long in NEM for a mid-term swing whi…
M/I Homes (MHO) combines a low-teens ROE, positive free cash flow and conservative leverage with a sub-10x P/E multiple and diversified regional footprint. In a housing market under pressure from higher rates, MHO's balance sheet, mortgage services unit and valuation profile create an asymmetric risk/reward for a mid-term long trade. Entry $141.11,…
Lemonade (LMND) has turned AI from marketing into measurable economics: faster claims automation, lower acquisition costs and new products (including a Tesla autonomous-vehicle policy) are compressing loss and expense ratios. The stock sold off into earnings-driven volatility; the pullback to $51.84 offers a tactical long with defined risk. I expec…
Vanda Pharmaceuticals (VNDA) has ripped higher on the Bysanti approval news, trading at $8.39 with heavy volume and a refreshed commercial story. The company’s market cap sits near $495M and revenue trends show modest growth, but negative free cash flow and a history of losses mean this is a high-risk, reward-managed long. This trade idea lays out …
Etsy's sale of Depop and a renewed capital-return program create a clearer, more cash-rich story. With free cash flow of $678M, a market cap near $5.0B and the stock trading around $52, the setup favors a calculated long over the next 11-45 trading days as green shoots of revenue quality and buyback-driven EPS lift materialize.
We upgrade SK Telecom to bullish on the view that management is near a decision point: a credible path to resume dividends and accelerate monetization of network and AI-related assets. The combination of yield appeal and clearer capital allocation could re-rate the stock. We lay out an actionable position with entry, stop and target levels and a li…
<p>Klarna has been a market talk candidate for a strategic re-rating if it can prove better-than-expected margins and sustained engagement in merchant partnerships. With live market data not available in the snapshot, this trade is conditional: a tactical long on a confirmed breakout with defined entry, stop and target. The risk/reward looks compel…
RingCentral (RNG) has the ingredients for a durable rally: accelerating AI attach rates, a large addressable unified-communications market, attractive free-cash-flow relative to market cap, and technical momentum. This trade lays out an entry at $35.00, a stop at $30.00 and a $50.00 target with horizon-specific guidelines and risk management.
Blue Owl Capital (OWL) has taken a hit from headlines about halted BDC redemptions and a rumored financing shortfall, but recent institutional purchases of $1.4B of assets at near-par plus strong free cash flow and a double-digit short interest create a tactical long opportunity. Entry at $10.45 with a stop at $9.25 and a primary target of $14.00 o…
Nike is trading below key moving averages after a pullback that priced in tariff headwinds and softer China demand. With a $92.5B market cap, $2.48B of free cash flow and a 2.46% dividend yield, the balance sheet and brand give Nike room to recover. Catalysts over the next 3-6 months - including a Supreme Court ruling easing tariff risk (02/23/2026…
Bloom Energy is trading as a high conviction play on AI data-center power reliability. The company showed 37% revenue growth in 2025 to $2.0B, Q4 revenue of $777.7M and a reported $20B backlog, and it is guiding to roughly $3.1B in 2026. Valuation is rich (market cap ~$42.4B, P/S ~20.5, EV/S ~20.65) and leverage is meaningful, but accelerating dema…
Novo Nordisk shares cratered into a 52-week low after REDEFINE 4 failed to show non-inferiority versus Eli Lilly's tirzepatide. The market reaction is severe and technical momentum is decisively bearish. This trade idea outlines a tactical short with a precise entry at $40.605, a protective stop at $45.00 and a downside target at $34.00 over a mid-…
BNEFF is trading at $3.77 with improving moving averages, rising RSI (58.5) and a stretched short-interest profile (828,438 shares short as of 01/30/2026). For active traders willing to accept OTC liquidity and execution risk, a controlled long into confirmed strength offers an asymmetric payoff: upside to $4.50 within a 45-trading-day window again…
Prada's reported purchase of Versace and progress on tech collaborations have rattled the stock but the deal size (~$1.375B) is under 10% of Prada's $14.1B market cap and should be manageable. Technicals and margin tailwinds leave room for a mid-term bounce toward $14. A disciplined entry at $11.00 with a $9.90 stop and a $14.00 target provides a d…
InnovAge (INNV) has been through litigation and volatility; recent moves suggest much of the bad news is already priced into the stock. Revenue growth and improving margins give a plausible path to upside, but high valuation multiples and regulatory sensitivity make this a medium-risk trade. Enter on weakness, size carefully, and use a defined stop…
Astera Labs' connectivity silicon for data-center and AI systems has been punished with the broader AI hardware downturn. For disciplined, patient buyers willing to accept execution and execution-risk, the current environment offers an asymmetric opportunity: limited near-term upside priced in, long-term upside tied to secular AI and hyperscaler up…
Apple is a cash-generating machine built around a 2.5 billion installed base. Valuation is rich but reasonable given $123B free cash flow and a durable services ramp. We outline a mid-term swing trade that captures upside from product cycles and services momentum while limiting downside with a tight stop.
Novo Nordisk (NVO) has been hammered on trial headlines and short-term fears, but underlying demand for weight-loss therapies and expanding oral formulations support a mid-term trade. At $47.42 the stock reflects pessimism about 2026 sales that may already be priced in. This trade targets a rebound as Wegovy adoption steadies and market growth expe…
Alphabet is investing heavily in AI infrastructure and that shows up in higher capex talk. Don’t confuse temporary spend with impaired economics: the company still generates $73.3B of free cash flow, trades at ~29x earnings, and Google Cloud growth is re-accelerating. This trade targets a rebound toward the 52-week highs as AI monetization and ente…
I argue Alphabet (GOOGL) is a tactical buy over the next 45 trading days. The SpaceX IPO and high-profile long-duration bond issuance are likely to shift investor allocations and long-term rates in ways that favor growth-with-quality names. Alphabet’s core advantages - pervasive distribution, cloud and AI infrastructure, and entrenched ad marketpla…
Hemisphere Energy (HMENF) is an OTC energy name trading near $1.62 with steady technical momentum, limited days-to-cover short interest, and recent volume spikes that suggest institutional size moves are unlikely to blow the stock around. For retirees or conservative allocators who want a modest allocation to small-cap energy, this is a structured …
The headline chart for Continental (CTTAY) understates the company's operational momentum after a corporate separation. Adjusted for the spin-off, technicals are bullish, industry secular growth in ADAS and vehicle electrification supports higher earnings, and OTC positioning provides a favorable risk/reward for a mid-term swing trade. Entry $8.70,…
PTC Therapeutics is transitioning from royalty receipts to product-led growth centered on Sephience (PKU). With a market cap near $5.7B, strong free cash flow generation and an undemanding EV/EBITDA multiple, PTCT offers a structured long opportunity: entry $70.60, target $95.00, stop $58.00, trade horizon 180 trading days.
